<code id='857D95B349'></code><style id='857D95B349'></style>
    • <acronym id='857D95B349'></acronym>
      <center id='857D95B349'><center id='857D95B349'><tfoot id='857D95B349'></tfoot></center><abbr id='857D95B349'><dir id='857D95B349'><tfoot id='857D95B349'></tfoot><noframes id='857D95B349'>

    • <optgroup id='857D95B349'><strike id='857D95B349'><sup id='857D95B349'></sup></strike><code id='857D95B349'></code></optgroup>
        1. <b id='857D95B349'><label id='857D95B349'><select id='857D95B349'><dt id='857D95B349'><span id='857D95B349'></span></dt></select></label></b><u id='857D95B349'></u>
          <i id='857D95B349'><strike id='857D95B349'><tt id='857D95B349'><pre id='857D95B349'></pre></tt></strike></i>

          fashion

          fashion

          author:focus    Page View:5
          Colorful one hundred dollar bills -- health tech coverage from STAT
          Adobe

          Hospitals aren’t usually in the business of selling technology tools. But that’s changing thanks to a collision of financial pressures and an explosion of new technology that could both improve patients’ health and ease the burden of administrative tasks on limited staff.

          At the J.P. Morgan Healthcare conference, an exclusive, invitation-only event for investors, several influential health systems like Mayo Clinic and Mass General Brigham doubled down on new revenue streams including advising companies building artificial intelligence tools or licensing out custom built products as they brace for a tough 2024.

          advertisement

          Selling tech isn’t entirely new: a subset of hospitals and academic centers have been licensing out risk models and health record tools for decades. But now, a “perfect storm” of shrinking profit margins and philanthropic dollars, workforce shortages and rising labor costs is driving more hospitals to explore selling new technology they have built, like scheduling or clinical note summary tools, more than they have before, according to Dana Rollison, chief data officer at Moffitt Cancer Center.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Manchin plays down potential 3rd
          Manchin plays down potential 3rd

          7:36Sen.JoeManchinandJonHuntsmanJr.speakwithABCNewsabouttheNoLabelsgroupinManchester,N.H,July17,2023

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

          SusanGalbraith,AstraZeneca’sheadofcancerresearchanddevelopment,speaksataSTATeventin2023.MarieMillerf